Evidence map›Paper›PMID 39263855›Full record

ArticleEuropean journal of haematology2025

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

C Bucelli, I Capodanno, M C Miggiano, F Cavazzini, S Leonetti Crescenzi, S Russo, I Carmosino, M Annunziata, F Sorà, M Bonifacio and 32 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

C BucelliHematology Division, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy.
I CapodannoHematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.ORCID https://orcid.org/0000-0002-6091-1899
M C MiggianoHematology Department, San Bortolo Hospital, Vicenza, Italy.
F CavazziniHematology Unit, University of Ferrara, Ferrara, Italy.
S Leonetti CrescenziHematology, San Giovanni Hospital, Rome, Italy.
S RussoHematology, University of Messina, Messina, Italy.
I CarmosinoHematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Rome, Italy.
M AnnunziataHematology Unit, Cardarelli Hospital, Naples, Italy.
F SoràInstitute of Hematology, Policlinico Universitario A. Gemelli, "Cattolica" University, Rome, Italy.ORCID https://orcid.org/0000-0002-9607-5298
M BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
L LucianoHematology, University Federico II, Naples, Italy.
G CaocciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
G LoglisciHematology, Vito Fazzi Hospital, Lecce, Italy.
C ElenaHematology, Policlinico San Matteo, University of Pavia, Pavia, Italy.
F LunghiDivision of Hematology and BMT, IRCCS San Raffaele Hospital, Milan, Italy.
R MullaiDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
I AttolicoHematology and Transplantation Unit, University of Bari, Bari, Italy.
G BinottoDepartment of Medicine, Hematology and Clinical Immunology, University of Padua, Padua, Italy.
E CrisàHematology, Ospedale Maggiore, Novara, Italy.
P SportolettiHematology, University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0002-5630-9862
A Di VeroliHematology, Belcolle Hospital, Viterbo, Italy.
A R ScortechiniHematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.
A P LeporaceHematology Unit Azienda Ospedaliero Universitaria Sant'Andrea, Roma, Italy.
A MaggiHematology, San Giuseppe Moscati Hospital, Taranto, Italy.
M CrugnolaHematology, University of Parma, Parma, Italy.
F StagnoHematology, Ferrarotto Hospital, Catania, Italy.
R SancettaHematology Unit, Dell'Angelo Hospital, Venezia-Mestre, Italy.
P MurganoDivision of Hematology, Sant'Elia Hospital, Caltanissetta, Italy.
D RapezziHematology, AO Santa Croce e Carle, Cuneo, Italy.
D LuziOnco-Hematology Department, AO Santa Maria, Terni, Italy.
D I VincelliHematology, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy.
S GalimbertiDepartment of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.
M BocchiaHematology, AOU Senese, Siena, Italy.
C FavaHematology, Mauriziano Hospital, Torino, Italy.
A MalatoHematology, Cervello Hospital, Palermo, Italy.
E AbruzzeseHematology, Sant'Eugenio Hospital, Roma, Italy.ORCID https://orcid.org/0000-0001-5228-6491
G SaglioDepartment of Clinical and Biological Sciences, University of Turin, Torino, Italy.
G SpecchiaSchool of Medicine, University of Bari, Bari, Italy.
M BrecciaHematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Rome, Italy.ORCID https://orcid.org/0000-0003-1163-6162
A IurloHematology Division, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-4401-0812
M TiribelliDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0001-9449-2621
R LatagliataHematology, Belcolle Hospital, Viterbo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP-CML patients.

methodsA retrospective analysis was conducted on 332 CP-CML patients aged 75 years or older among 1929 diagnosed from January 2012 to December 2019 followed at 36 participating Hematology Centers involved in the "Campus CML" project.

resultsAmong the patients analyzed, 85.8% received imatinib (IM) while 14.2% received second-generation TKIs (2G-TKI), 59.5% dasatinib, and 40.5% nilotinib. Most patients initiated IM at standard dose (67.3%) while 32.7% at reduced dose. A similar trend was observed with 2G-TKIs. The cumulative incidence of permanent TKI discontinuation at 12 months was 28.4%, primarily due to primary resistance (10.1%) and extra-hematologic toxicity (9.5%), with no significant difference between IM and 2G-TKI groups. Following the introduction of generic IM in Italy in 2018, IM usage increased significantly compared with 2G-TKIs.

conclusionsIM was in our Centers the preferred frontline therapy for older CP-CML patients, with increasing utilization after the introduction of generic formulations. However, 2G-TKIs are still used in a substantial proportion of patients, suggesting individualized physician assessments regarding patient suitability and expectations. Further investigation is needed to assess efficacy and safety of reduced TKI doses in this patient population.

Indexed as

Protein Kinase InhibitorsAgedAged, 80 and overAge FactorsDrug Resistance, NeoplasmFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseMaleRetrospective StudiesTreatment OutcomeProtein Kinase Inhibitorschronic myeloid leukemiacomorbiditiesdose optimizationefficacyoldersafetytyrosine kinase inhibitorvery elderly

Identifiers

PMID39263855
PMCPMC11613622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.